Document is current
Any future updates will be listed below
-
Authors
Miyazaki, Yasushi
Matsumura, Itaru
Arita, Takeshi
Fukuda, Ryouko
Yamanaka, Mie
-
Funding
Funding for this research was provided by:
Daiichi Sankyo Co., Ltd.
- License Information
-
More Information
Article History
Received: 1 September 2025
Revised: 5 February 2026
Accepted: 6 February 2026
First Online: 26 February 2026
Declarations
:
: Yasushi Miyazaki reports support for the present manuscript from Daiichi Sankyo Co., Ltd.; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Daiichi Sankyo Co., Ltd., Astellas, Novartis, Sumitomo Pharma, Bristol Myers Squibb, AbbVie, and Chugai Pharmaceutical Co., Ltd; a leadership or fiduciary role for the Japan Adult Leukemia Study Group; and membership of the International Journal of Hematology Editorial Board. Itaru Matsumura reports grants or contracts from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., AbbVie GK, Asahi Kasei Pharma Corporation, Sumitomo Pharma, Taiho Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd; consulting fees from Otsuka Pharmaceutical Co., Ltd.; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Chugai Pharmaceutical Co., Ltd, Novartis Pharma, Novartis, Pfizer Japan, AbbVie, Ono Pharmaceutical Co., Ltd., Sanofi, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., and Astellas Pharma. Takeshi Arita has no conflicts of interest to declare. Ryouko Fukuda and Mie Yamanaka are employees of Daiichi Sankyo Co., Ltd.
